Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 8/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 3/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279444 | 1.00 | KCNH2 (0.43) | KCNH2CACNA1IMCHR1ADRA2AADRA1A | |
| SCHEMBL4278378 | 0.90 | KCNH2 (0.54) | KCNH2CACNA1IMCHR1ADRA2AADRA1A | |
| SCHEMBL4278380 | 0.90 | KCNH2 (0.54) | KCNH2CACNA1IMCHR1ADRA2AADRA1A | |
| SCHEMBL4284164 | 0.86 | KCNH2 (0.49) | KCNH2CACNA1IMCHR1ADRA2AADRA1A | |
| SCHEMBL4277296 | 0.86 | KCNH2 (0.49) | KCNH2CACNA1IMCHR1ADRA2AADRA1A | |
| SCHEMBL4277291 | 0.86 | KCNH2 (0.49) | KCNH2CACNA1IMCHR1ADRA2AADRA1A | |
| SCHEMBL4274764 | 0.85 | CACNA1I (0.51) | KCNH2CACNA1IMCHR1ADRA2AADRA1A | |
| SCHEMBL4274759 | 0.85 | CACNA1I (0.51) | KCNH2CACNA1IMCHR1ADRA2AADRA1A | |
| SCHEMBL8371920 | 0.83 | KCNH2 (0.47) | KCNH2CACNA1IMCHR1ADRA2AADRA1A | |
| SCHEMBL13568425 | 0.81 | MCHR1 (0.40) | KCNH2CACNA1IMCHR1ADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009146539-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-12-10 | — | — | WO | disclosed |
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-12-03 | — | — | US | disclosed |
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-12-03 | — | — | US | disclosed |
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNA1H | KCNH2 46/4885CACNA1I 2/4885MCHR1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.